Activation of NLRP3 inflammasome enhances the proliferation and migration of A549 lung cancer cells

Oncology Reports

Volumn 35, Issue 4, 2016, Pages 2053-2064

  Wang, Yanli ^a   Kong, Hui ^a   Zeng, Xiaoning ^a   Liu, Wenrui ^a   Wang, Zailiang ^a   Yan, Xiaopei ^a   Wang, Hong ^a   Xie, Weiping ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Lung cancer; Migration; NLRP3 inflammasome; Proliferation

Indexed keywords

ADENOSINE TRIPHOSPHATE; CRYOPYRIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOPROTEIN; PROTEIN KINASE B; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN; NLRP3 PROTEIN, HUMAN;

A549 CELL LINE; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPOPOLYSACCHARIDES; LUNG NEOPLASMS; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84958546545     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.4569     Document Type: Article

References (57)

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
2. Tarassishin L, Casper D and Lee SC: Aberrant expression of interleukin-1 and inflammasome activation in human malignant gliomas. PLoS One 9: e103432, 2014.
3. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C and Hermoso MA: Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014: 149185, 2014.
4. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
5. Mantovani A: Cancer: Inflaming metastasis. Nature 457: 36-37, 2009.
6. Ozaki E, Campbell M and Doyle SL: Targeting the NLRP3 inflammasome in chronic inflammatory diseases: Current perspectives. J Inflamm Res 8: 15-27, 2015.
7. Kolb R, Liu GH, Janowski AM, Sutterwala FS and Zhang W: Inflammasomes in cancer: A double-edged sword. Protein Cell 5: 12-20, 2014.
8. Okamoto M, Liu W, Luo Y, Tanaka A, Cai X, Norris DA, Dinarello CA and Fujita M: Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J Biol Chem 285: 6477-6488, 2010.
9. Zhu Z, Zhong S and Shen Z: Targeting the inflammatory pathways to enhance chemotherapy of cancer. Cancer Biol Ther 12: 95-105, 2011.
10. Meng XF, Wang XL, Tian XJ, Yang ZH, Chu GP, Zhang J, Li M, Shi J and Zhang C: Nod-like receptor protein 1 inflammasome mediates neuron injury under high glucose. Mol Neurobiol 49: 673-684, 2014.
11. Fortin CF, Ear T and McDonald PP: Autocrine role of endogenous interleukin-18 on inflammatory cytokine generation by human neutrophils. FASEB J 23: 194-203, 2009.
12. Rivollier A, Mazzorana M, Tebib J, Piperno M, Aitsiselmi T, Rabourdin-Combe C, Jurdic P and Servet-Delprat C: Immature dendritic cell transdifferentiation into osteoclasts: A novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 104: 4029-4037, 2004.
13. Yu Y, Arora A, Min W, Roifman CM and Grunebaum E: EdU incorporation is an alternative non-radioactive assay to [(3)H] thymidine uptake for in vitro measurement of mice T-cell proliferations. J Immunol Methods 350: 29-35, 2009.
14. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
15. Tania M, Khan MA and Fu J: Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biol 35: 7335-7342, 2014.
16. Zitvogel L, Kepp O, Galluzzi L and Kroemer G: Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 13: 343-351, 2012.
17. Janowski AM, Kolb R, Zhang W and Sutterwala FS: Beneficial and Detrimental Roles of NLRs in Carcinogenesis. Front Immunol 4: 370, 2013.
18. Strowig T, Henao-Mejia J, Elinav E and Flavell R: Inflammasomes in health and disease. Nature 481: 278-286, 2012.
19. Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB, Herfarth HH, Jobin C and Ting JP: The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 207: 1045-1056, 2010.
20. Zhang A, Wang P, Ma X, Yin X, Li J, Wang H, Jiang W, Jia Q and Ni L: Mechanisms that lead to the regulation of NLRP3 inflammasome expression and activation in human dental pulp fibroblasts. Mol Immunol 66: 253-262, 2015.
21. Sagulenko V, Thygesen SJ, Sester DP, Idris A, Cridland JA, Vajjhala PR, Roberts TL, Schroder K, Vince JE, Hill JM, et al: AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC. Cell Death Differ 20: 1149-1160, 2013.
22. Maelfait J, Vercammen E, Janssens S, Schotte P, Haegman M, Magez S and Beyaert R: Stimulation of Toll-like receptor 3 and 4 induces interleukin-1beta maturation by caspase-8. J Exp Med 205: 1967-1973, 2008.
23. Antonopoulos C, El Sanadi C, Kaiser WJ, Mocarski ES and Dubyak GR: Proapoptotic chemotherapeutic drugs induce noncanonical processing and release of IL-1beta via caspase-8 in dendritic cells. J Immunol 191: 4789-4803, 2013.
24. Gringhuis SI, Kaptein TM, Wevers BA, Theelen B, van der Vlist M, Boekhout T and Geijtenbeek TB: Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1 via a noncanonical caspase-8 inflammasome. Nat Immunol 13: 246-254, 2012.
25. Li S, Sun R, Chen Y, Wei H and Tian Z: TLR2 controls the development of hepatocellular carcinoma by reducing interleukin18-mediated immunosuppression. Cancer Res, Jan. 19, 2015 (Epub ahead of print). doi: 10.1158/0008-5472. CAN-142371.
26. Saijo Y, Tanaka M, Miki M, Usui K, Suzuki T, Maemondo M, Hong X, Tazawa R, Kikuchi T, Matsushima K, et al: Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: In vivo analysis of tumor-stromal interaction. J Immunol 169: 469-475, 2002.
27. Wang L, Zhang LF, Wu J, Xu SJ, Xu YY, Li D, Lou JT and Liu MF: IL-1-mediated repression of microRNA-101 is crucial for inflammation-promoted lung tumorigenesis. Cancer Res 74: 4720-4730, 2014.
28. Fabbi M, Carbotti G and Ferrini S: Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP. J Leukoc Biol 97: 665-675, 2015.
29. Rovina N, Hillas G, Dima E, Vlastos F, Loukides S, Veldekis D, Roussos C, Alhanatis M and Bakakos P: VEGF and IL-18 in induced sputum of lung cancer patients. Cytokine 54: 277-281, 2011.
30. Kim KE, Song H, Hahm C, Yoon SY, Park S, Lee HR, Hur DY, Kim T, Kim CH, Bang SI, et al: Expression of ADAM33 is a novel regulatory mechanism in IL-18-secreted process in gastric cancer. J Immunol 182: 3548-3555, 2009.
31. Kim KE, Song H, Kim TS, Yoon D, Kim CW, Bang SI, Hur DY, Park H and Cho DH: Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines. Oncogene 26: 1468-1476, 2007.
32. Kim J, Kim C, Kim TS, Bang SI, Yang Y, Park H and Cho D: IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway. Biochem Biophys Res Commun 344: 1284-1289, 2006.
33. Vidal-Vanaclocha F, Fantuzzi G, Mendoza L, Fuentes AM, Anasagasti MJ, Martín J, Carrascal T, Walsh P, Reznikov LL, Kim SH, et al: IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci USA 97: 734-739, 2000.
34. Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y and Voronov E: The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumorhost interactions. Cancer Metastasis Rev 25: 387-408, 2006.
35. Martín MJ, Calvo N, de Boland AR and Gentili C: Molecular mechanisms associated with PTHrP-induced proliferation of colon cancer cells. J Cell Biochem 115: 2133-2145, 2014.
36. Will M, Qin AC, Toy W, Yao Z, Rodrik-Outmezguine V, Schneider C, Huang X, Monian P, Jiang X, de Stanchina E, et al: Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov 4: 334-347, 2014.
37. Johannessen M and Moens U: Multisite phosphorylation of the cAMP response element-binDing protein (CREB) by a diversity of protein kinases. Front Biosci 12: 1814-1832, 2007.
38. Reddy VS, Valente AJ, Delafontaine P and Chandrasekar B: Interleukin-18/WNT1-inducible signaling pathway protein-1 signaling mediates human saphenous vein smooth muscle cell proliferation. J Cell Physiol 226: 3303-3315, 2011.
39. Hosotani Y, Kashiwamura S, Kimura-Shimmyo A, Sekiyama A, Ueda H, Ikeda T, Mimura O and Okamura H: Interleukin-18 prevents apoptosis via PI3K/Akt pathway in normal human keratinocytes. J Dermatol 35: 514-524, 2008.
40. Fix C, Bingham K and Carver W: Effects of interleukin-18 on cardiac fibroblast function and gene expression. Cytokine 53: 19-28, 2011.
41. Yang KY, Bae WS, Kim MJ, Bae YC, Kim YJ, Kim HJ, Nam SH and Ahn DK: Participation of the central p38 and ERK1/2 pathways in IL-1-induced sensitization of nociception in rats. Prog Neuropsychopharmacol Biol Psychiatry 46: 98-104, 2013.
42. Venkatesan B, Valente AJ, Reddy VS, Siwik DA and Chandrasekar B: Resveratrol blocks interleukin-18-EMMPRIN cross-regulation and smooth muscle cell migration. Am J Physiol Heart Circ Physiol 297: H874-H886, 2009.
43. Chang MC, Hung HP, Lin LD, Shyu YC, Wang TM, Lin HJ, Chan CP, Huang CC and Jeng JH: Effect of interleukin-1 on ICAM-1 expression of dental pulp cells: Role of PI3K/Akt, MEK/ERK, and cyclooxygenase. Clin Oral Investig 19: 117-126, 2015.
44. Yan B, Zhang W, Jiang LY, Qin WX and Wang X: Reduced E-cadherin expression is a prognostic biomarker of non-small cell lung cancer: A meta-analysis based on 2395 subjects. Int J Clin Exp Med 7: 4352-4356, 2014.
45. Wang R, Ke ZF, Wang F, Zhang WH, Wang YF, Li SH and Wang LT: GOLPH3 overexpression is closely correlated with poor prognosis in human non-small cell lung cancer and mediates its metastasis through upregulating MMP-2 and MMP-9. Cell Physiol Biochem 35: 969-982, 2015.
46. Fiorentini C, Bodei S, Bedussi F, Fragni M, Bonini SA, Simeone C, Zani D, Berruti A, Missale C, Memo M, et al: GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity. Exp Cell Res 323: 100-111, 2014.
47. Bandapalli OR, Ehrmann F, Ehemann V, Gaida M, Macher-Goeppinger S, Wente M, Schirmacher P and Brand K: Down-regulation of CXCL1 inhibits tumor growth in colorectal liver metastasis. Cytokine 57: 46-53, 2012.
48. Gogali A, Charalabopoulos K, Zampira I, Konstantinidis AK, Tachmazoglou F, Daskalopoulos G, Constantopoulos SH and Dalavanga Y: Soluble adhesion molecules E-cadherin, intercellular adhesion molecule-1, and E-selectin as lung cancer biomarkers. Chest 138: 1173-1179, 2010.
49. Wu Y and Zhou BP: Inflammation: A driving force speeds cancer metastasis. Cell Cycle 8: 3267-3273, 2009.
50. Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T and Sugimachi K: Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res 6: 4789-4796, 2000.
51. Grant JL, Fishbein MC, Hong LS, Krysan K, Minna JD, Shay JW, Walser TC and Dubinett SM: A novel molecular pathway for Snail-dependent, SPARC-mediated invasion in non-small cell lung cancer pathogenesis. Cancer Prev Res (Phila) 7: 150-160, 2014.
52. Lee CH, Chang JS, Syu SH, Wong TS, Chan JY, Tang YC, Yang ZP, Yang WC, Chen CT, Lu SC, et al: IL-1 promotes malignant transformation and tumor aggressiveness in oral cancer. J Cell Physiol 230: 875-884, 2015.
53. Jee YS, Jang TJ and Jung KH: Prostaglandin E(2) and interleukin-1 reduce E-cadherin expression by enhancing snail expression in gastric cancer cells. J Korean Med Sci 27: 987-992, 2012.
54. Bani-Hani AH, Leslie JA, Asanuma H, Dinarello CA, Campbell MT, Meldrum DR, Zhang H, Hile K and Meldrum KK: IL-18 neutralization ameliorates obstruction-induced epithelialmesenchymal transition and renal fibrosis. Kidney Int 76: 500-511, 2009.
55. Helmy A, Guilfoyle MR, Carpenter KLH, Pickard JD, Menon DK and Hutchinson PJ: Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: A phase II randomized control trial. J Cereb Blood Flow Metab 34: 845-851, 2014.
56. Wang CC, Li H, Zhang M, Li XL, Yue LT, Zhang P, Zhao Y, Wang S, Duan RN, Li YB, et al: Caspase-1 inhibitor ameliorates experimental autoimmune myasthenia gravis by innate dendric cell IL-1-IL-17 pathway. J Neuroinflammation 12: 118, 2015.
57. Gu H, Xie M, Xu L, Zheng X, Yang Y and Lv X: The protective role of interleukin-18 binDing protein in a murine model of cardiac ischemia/reperfusion injury. Transpl Int 28: 1436-1444, 2015.